MEBIAS
Mining the full potential of GPCR signaling to innovate novel drugs.
Mebias
Conformation Driven Drug Discovery for GPCRs
Our proprietary membrane protein-NMR drug discovery platform identifies highly signaling-pathway selective molecules that bind to G-protein coupled receptor (GPCR) targets, eliminating on-target adverse effects that limit therapeutic index.
Our Progress
We know the value of innovative drug discovery and development…
MEBIAS’ business model is comprised of partnering and advancing its own molecules into early clinical development. Six years since its founding, the company has validated its unique drug discovery, identified a novel preclinical mu-opioid candidate entering Phase 1 human clinical studies in 2022, and currently developing Sphingosine 1-phosphate receptor (S1PR1) agonists for the treatment of neuropathic pain.
Address
3675 Market Street Suite 200
Philadelphia, PA 19104
Call Us
267–536–4125
EMAIL US
Protein.dynamics@mebiasdiscovery.com